BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 21339744)

  • 1. Metal-free imidazolium salts inhibit the growth of hepatocellular carcinoma in a mouse model.
    Gopalan B; Ke Z; Zhang C; Kng Y; Suhaimi NA; Riduan SN; Zhang Y; Zhuo L
    Lab Invest; 2011 May; 91(5):744-51. PubMed ID: 21339744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic effect of a multi-targeted imidazolium compound in hepatocellular carcinoma.
    Gopalan B; Narayanan K; Ke Z; Lu T; Zhang Y; Zhuo L
    Biomaterials; 2014 Aug; 35(26):7479-87. PubMed ID: 24912819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin.
    Ou DL; Lee BS; Lin LI; Liou JY; Liao SC; Hsu C; Cheng AL
    Mol Cancer; 2014 Jan; 13():2. PubMed ID: 24387108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survivin knockdown by short hairpin RNA abrogates the growth of human hepatocellular carcinoma xenografts in nude mice.
    Zhang R; Ma L; Zheng M; Ren J; Wang T; Meng Y; Zhao J; Jia L; Yao L; Han H; Li K; Yang A
    Cancer Gene Ther; 2010 Apr; 17(4):275-88. PubMed ID: 19876077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Xylocydine, a novel Cdk inhibitor, is an effective inducer of apoptosis in hepatocellular carcinoma cells in vitro and in vivo.
    Cho SJ; Lee SS; Kim YJ; Park BD; Choi JS; Liu L; Ham YM; Moon Kim B; Lee SK
    Cancer Lett; 2010 Jan; 287(2):196-206. PubMed ID: 19616371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects and mechanisms of silibinin on human hepatocellular carcinoma xenografts in nude mice.
    Cui W; Gu F; Hu KQ
    World J Gastroenterol; 2009 Apr; 15(16):1943-50. PubMed ID: 19399925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The over-expression of survivin enhances the chemotherapeutic efficacy of YM155 in human hepatocellular carcinoma.
    Xia H; Chen J; Shi M; Deivasigamani A; Ooi LL; Hui KM
    Oncotarget; 2015 Mar; 6(8):5990-6000. PubMed ID: 25714025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extract Derived from
    Huang XF; Chang KF; Lee SC; Sheu GT; Li CY; Weng JC; Hsiao CY; Tsai NM
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33050385
    [No Abstract]   [Full Text] [Related]  

  • 9. Blockade of Wnt-1 signaling leads to anti-tumor effects in hepatocellular carcinoma cells.
    Wei W; Chua MS; Grepper S; So SK
    Mol Cancer; 2009 Sep; 8():76. PubMed ID: 19778454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear translocation of survivin in hepatocellular carcinoma: a key to cancer cell growth?
    Moon WS; Tarnawski AS
    Hum Pathol; 2003 Nov; 34(11):1119-26. PubMed ID: 14652813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-myc downstream regulated gene1/Cap43 overexpression suppresses tumor growth by hepatic cancer cells through cell cycle arrest at the G0/G1 phase.
    Akiba J; Murakami Y; Noda M; Watari K; Ogasawara S; Yoshida T; Kawahara A; Sanada S; Yasumoto M; Yamaguchi R; Kage M; Kuwano M; Ono M; Yano H
    Cancer Lett; 2011 Nov; 310(1):25-34. PubMed ID: 21775055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (-)-Oleocanthal inhibits growth and metastasis by blocking activation of STAT3 in human hepatocellular carcinoma.
    Pei T; Meng Q; Han J; Sun H; Li L; Song R; Sun B; Pan S; Liang D; Liu L
    Oncotarget; 2016 Jul; 7(28):43475-43491. PubMed ID: 27259268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamins K2, K3 and K5 exert in vivo antitumor effects on hepatocellular carcinoma by regulating the expression of G1 phase-related cell cycle molecules.
    Kuriyama S; Hitomi M; Yoshiji H; Nonomura T; Tsujimoto T; Mitoro A; Akahane T; Ogawa M; Nakai S; Deguchi A; Masaki T; Uchida N
    Int J Oncol; 2005 Aug; 27(2):505-11. PubMed ID: 16010434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silencing of signal transducer and activator of transcription 3 expression by RNA interference suppresses growth of human hepatocellular carcinoma in tumor-bearing nude mice.
    Li J; Piao YF; Jiang Z; Chen L; Sun HB
    World J Gastroenterol; 2009 Jun; 15(21):2602-8. PubMed ID: 19496189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma.
    Kong J; Kong F; Gao J; Zhang Q; Dong S; Gu F; Ke S; Pan B; Shen Q; Sun H; Zheng L; Sun W
    Mol Cancer; 2014 Jan; 13():7. PubMed ID: 24418169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survivin promotes cell proliferation in human hepatocellular carcinoma.
    Ito T; Shiraki K; Sugimoto K; Yamanaka T; Fujikawa K; Ito M; Takase K; Moriyama M; Kawano H; Hayashida M; Nakano T; Suzuki A
    Hepatology; 2000 May; 31(5):1080-5. PubMed ID: 10796883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Romidepsin induces G2/M phase arrest via Erk/cdc25C/cdc2/cyclinB pathway and apoptosis induction through JNK/c-Jun/caspase3 pathway in hepatocellular carcinoma cells.
    Sun WJ; Huang H; He B; Hu DH; Li PH; Yu YJ; Zhou XH; Lv Z; Zhou L; Hu TY; Yao ZC; Lu MD; Shen X; Zheng ZQ
    Biochem Pharmacol; 2017 Mar; 127():90-100. PubMed ID: 28012958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab enhances chemosensitivity of hepatocellular carcinoma to adriamycin related to inhibition of survivin expression.
    Xiong YQ; Sun HC; Zhu XD; Zhang W; Zhuang PY; Zhang JB; Xu HX; Kong LQ; Wu WZ; Qin LX; Tang ZY
    J Cancer Res Clin Oncol; 2011 Mar; 137(3):505-12. PubMed ID: 20490863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survivin inhibitor YM155 suppresses gastric cancer xenograft growth in mice without affecting normal tissues.
    Cheng XJ; Lin JC; Ding YF; Zhu L; Ye J; Tu SP
    Oncotarget; 2016 Feb; 7(6):7096-109. PubMed ID: 26771139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sulfatase 1 (hSulf-1) reverses basic fibroblast growth factor-stimulated signaling and inhibits growth of hepatocellular carcinoma in animal model.
    Xu G; Ji W; Su Y; Xu Y; Yan Y; Shen S; Li X; Sun B; Qian H; Chen L; Fu X; Wu M; Su C
    Oncotarget; 2014 Jul; 5(13):5029-39. PubMed ID: 24970807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.